Connexins may play a critical role in cigarette smoke-induced pulmonary hypertension

Arch Toxicol. 2022 Jun;96(6):1609-1621. doi: 10.1007/s00204-022-03274-6. Epub 2022 Mar 27.

Abstract

Pulmonary hypertension (PH) is a chronic progressive disease characterized by pulmonary vasoconstriction and remodeling. It causes a gradual increase in pulmonary vascular resistance leading to right-sided heart failure, and may be fatal. Chronic exposure to cigarette smoke (CS) is an essential risk factor for PH group 3; however, smoking continues to be prevalent and smoking cessation is reported to be difficult. A majority of smokers exhibit PH, which leads to a concomitant increase in the risk of mortality. The current treatments for PH group 3 focus on vasodilation and long-term oxygen supplementation, and fail to stop or reverse PH-associated continuous vascular remodeling. Recent studies have suggested that pulmonary vascular endothelial dysfunction induced by CS exposure may be an initial event in the natural history of PH, which in turn may be associated with abnormal alterations in connexin (Cx) expression. The relationship between Cx and CS-induced PH development has not yet been directly investigated. Therefore, this review will describe the roles of CS and Cx in the development of PH and discuss the related downstream pathways. We also discuss the possible role of Cx in CS-induced PH. It is hoped that this review may provide new perspectives for early intervention.

Keywords: Cigarette; Connexins; Pulmonary hypertension.

Publication types

  • Review

MeSH terms

  • Cigarette Smoking* / adverse effects
  • Connexins / genetics
  • Humans
  • Hypertension, Pulmonary* / etiology
  • Hypertension, Pulmonary* / metabolism
  • Nicotiana
  • Vasoconstriction
  • Vasodilation

Substances

  • Connexins